LivaNova PLC (NASDAQ:LIVN) Receives Consensus Recommendation of “Buy” from Analysts

LivaNova PLC (NASDAQ:LIVN) has received an average recommendation of “Buy” from the eight ratings firms that are presently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating on the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $59.29.

LIVN has been the subject of a number of recent research reports. Robert W. Baird upped their price target on LivaNova from $55.00 to $61.00 and gave the stock an “outperform” rating in a research report on Thursday, May 8th. Barclays cut their price objective on LivaNova from $56.00 to $55.00 and set an “equal weight” rating for the company in a report on Thursday, May 8th. Needham & Company LLC reissued a “buy” rating and issued a $64.00 price objective on shares of LivaNova in a report on Tuesday, May 13th. Wolfe Research raised LivaNova from a “peer perform” rating to an “outperform” rating and set a $60.00 price objective for the company in a report on Tuesday, May 20th. Finally, Wall Street Zen downgraded LivaNova from a “strong-buy” rating to a “buy” rating in a report on Thursday, May 8th.

LivaNova Trading Down 1.2%

NASDAQ:LIVN opened at $43.43 on Wednesday. LivaNova has a twelve month low of $32.48 and a twelve month high of $57.35. The company has a quick ratio of 1.37, a current ratio of 1.58 and a debt-to-equity ratio of 0.53. The business has a 50 day moving average price of $44.85 and a two-hundred day moving average price of $43.23. The company has a market cap of $2.37 billion, a P/E ratio of -10.62 and a beta of 0.90.

Institutional Investors Weigh In On LivaNova

A number of large investors have recently added to or reduced their stakes in LIVN. Vanguard Group Inc. lifted its holdings in shares of LivaNova by 13.5% during the first quarter. Vanguard Group Inc. now owns 2,666,880 shares of the company’s stock worth $104,755,000 after buying an additional 316,993 shares in the last quarter. Capital Research Global Investors raised its stake in LivaNova by 19.1% in the fourth quarter. Capital Research Global Investors now owns 1,612,818 shares of the company’s stock valued at $74,690,000 after purchasing an additional 258,730 shares in the last quarter. AQR Capital Management LLC raised its stake in LivaNova by 111.7% in the first quarter. AQR Capital Management LLC now owns 1,571,295 shares of the company’s stock valued at $60,809,000 after purchasing an additional 829,115 shares in the last quarter. Dimensional Fund Advisors LP raised its stake in LivaNova by 8.9% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,310,990 shares of the company’s stock valued at $60,710,000 after purchasing an additional 107,693 shares in the last quarter. Finally, Redmile Group LLC raised its stake in LivaNova by 19.3% in the fourth quarter. Redmile Group LLC now owns 1,043,539 shares of the company’s stock valued at $48,326,000 after purchasing an additional 168,500 shares in the last quarter. Institutional investors own 97.64% of the company’s stock.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.